MedTrace Logo

FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

NCT06620042 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-11-10

No results posted yet for this study

Summary

This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI.

Conditions

Interventions

DRUG

Ketamine

Open-label Ketamine

OTHER

Functional magnetic resonance imaging (fMRI)

Functional magnetic resonance imaging (fMRI) of the brain

Sponsors & Collaborators

  • Brian Barnett

    lead OTHER

Principal Investigators

  • Brian Barnett, MD · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-12
Primary Completion
2025-10-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06620042 on ClinicalTrials.gov